Vemlidy · DIN 02464241 · 25 mg · tablet
Limited Use, Reason for Use code 517, 518, 519, 520, 521 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 517, 518, 519, 520, 521 required
Write on scriptone applicable Reason for Use code, 517 or 518 or 519 or 520 or 521 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 517, 518, 519, 520, 521
Reason for Use code 517
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
OR
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 518
For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 519
Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 520
Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 521
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vemlidy · DIN 02464241
Manufacturer: Gilead Sciences Canada, Inc.; listing date 2026-01-30
Health Canada: Marketed since 2017-06-20 · brand VEMLIDY · ATC J05AF13 TENOFOVIR ALAFENAMIDE · form Tablet · route Oral · ingredients TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 25 MG · company Gilead sciences canada inc · schedule Prescription
Vemlidy: Formulary list price $19.55 per unit (the source does not state the unit; exact figure $19.5537). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02464241)
Source record
DIN 02464241: Vemlidy
Raw flags: sec12=Y, sec3=Y
Item: 081800422; group id 112; item number 0194; lccId 00425; manufacturer id GIL
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $19.5537; ministry $19.5537
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02464241
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95241
Shortage status: not checked (no credentials)